Cargando…

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer

Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Satoshi, Patil, Rameshwar, Portilla-Arias, Jose, Ding, Hui, Konda, Bindu, Espinoza, Andres, Mongayt, Dmitriy, Markman, Janet L., Elramsisy, Adam, Phillips, H. Westley, Black, Keith L., Holler, Eggehard, Ljubimova, Julia Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280290/ https://www.ncbi.nlm.nih.gov/pubmed/22355336 http://dx.doi.org/10.1371/journal.pone.0031070

Ejemplares similares

Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(β-L-Malic Acid)
por: Patil, Rameshwar, et al.
Publicado: (2012)

Quantitative Analysis of PMLA Nanoconjugate Components after Backbone Cleavage
por: Ding, Hui, et al.
Publicado: (2015)

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
por: Ljubimova, Julia Y., et al.
Publicado: (2014)

Multifunctional Nanopolymers for Blood–Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1
por: Patil, Rameshwar, et al.
Publicado: (2021)

Coarse particulate matter (PM(2.5–10)) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains
por: Ljubimova, Julia Y., et al.
Publicado: (2018)

Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models
por: Hu, Jinwei, et al.
Publicado: (2010)

Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma
por: Patil, Rameshwar, et al.
Publicado: (2020)

Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents
por: Ljubimova, Julia Y., et al.
Publicado: (2021)

Green nanobiopolymers for ecological applications: a step towards a sustainable environment
por: Chincholikar, Preeti, et al.
Publicado: (2023)

Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
por: Israel, Liron L., et al.
Publicado: (2022)

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
por: Galstyan, Anna, et al.
Publicado: (2019)

Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
por: Galstyan, Anna, et al.
Publicado: (2020)

Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
por: Galstyan, Anna, et al.
Publicado: (2020)

Laminin isoform expression in breast tumors
por: Holler, Eggehard
Publicado: (2005)

Quantum dot loaded immunomicelles for tumor imaging
por: Papagiannaros, Aristarchos, et al.
Publicado: (2010)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

The effect of weight in the outcomes of meningioma patients
por: Dickinson, Holly, et al.
Publicado: (2013)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
por: Zoeller, Jason J., et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model
por: Hu, Jinwei, et al.
Publicado: (2007)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
por: Niu, Hardy, et al.
Publicado: (2017)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
por: Sood, Neelam, et al.
Publicado: (2014)

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
por: Hossein-Nejad-Ariani, Hanieh, et al.
Publicado: (2019)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Genetic distance for serum protein complex of some particular local cattle breeds of Eastern Europe
por: Istomin, AA, et al.
Publicado: (1982)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations
por: Zheng, Qingmei, et al.
Publicado: (2022)

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
por: Sebastian, Anusha, et al.
Publicado: (2016)

Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells
por: Rosado-Galindo, Heizel, et al.
Publicado: (2023)

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Near infrared planar tumor imaging and quantification using nanosized Alexa 750-labeled phospholipid micelles
por: Papagiannaros, Aristarchos, et al.
Publicado: (2009)

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Wang, Chao-Qun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r7buc5sgoi1fr8njrnj5l5c3us